Company / Operating Cash Flow
Kiniksa Pharmaceuticals International, plc Operating Cash Flow History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
$138.0M
FY2025
5-year range
-$158.4M / $138.0M
FY2021-FY2025
Trend
+437.1%
vs FY2024
Sector context
#47 of 216
Health Care
What the data says
Operating Cash Flow changed +437% YoY in FY2025, a notable deviation from the 8-year average annual change of +75%.
Based on SEC 10-K filings.
$138M in FY2025 with a 3-year CAGR of +187.5%. Top quartile in the Health Care sector.
Improved from $13M to $138M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- +187.5%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 22% in Health CareTop 22% of 216This company $138.0M Sector average $659.0M
▼
-79.1% below sector average
Key checks
Key Insights
- Kiniksa Pharmaceuticals International, plc's operating cash flow has grown for 4 consecutive years.
- 3-year CAGR of +187.5%, indicating consistent growth.
- In FY2025, operating cash flow increased 437.1% year-over-year.
- Ranks #47 out of 216 companies in the Health Care sector.
Company context
Key Data Points
- Negative profit margin: -10.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $138.0M | +437.1% |
| FY2024 | $25.7M | +93.1% |
| FY2023 | $13.3M | +129.1% |
| FY2022 | $5.8M | +103.7% |
| FY2021 | -$158.4M | -16.0% |
| FY2020 | -$136.5M | +13.8% |
| FY2019 | -$158.4M | -95.5% |
| FY2018 | -$81.0M | -61.3% |
| FY2017 | -$50.2M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026